CRIF1 promotes the progression of non-small-cell lung cancer by SIRT3- mediated deacetylation of PYCR1

In this study, the specific role and related mechanism of CRIF1 in non-small cell lung cancer (NSCLC) were explored in this research. TheRT-PCR, western blot and IHC assays were used to examine the expression level of CRIF1 in NSCLC tissue, tissue adjacent to carcinoma, NSCLC cell lines and human normal lung epithelial cells. Next, colony formation assay, Alamar blue Kit and EdU assays were employed to examine the proliferation of transfected A549 and NCI-H2009 cells. Measurement of mitochondrial permeability transition pore opening, ATP production and cellular oxygen consumption were used to evaluate the mitochondrial apoptosis of transfected NSCLC cells. Enzymatic activity assays for PYCR1, western blot and flow cytometry assays were used to explore the relationship between PYCR1 and CRIF1. The subcutaneous xenograft tumor mice model was established to explore the role of CRIF1 in vivo. Collectively, results revealed that CRIF1 was upregulated in NSCLC cells and tissues (p  <  0.001). CRIF1 promoted proliferation of NSCLC cells (p <  0.001). CRIF1 inhibited mitochondrial apoptosis in NSCLC cells (p <  0.05). Moreover, CRIF1 promoted PYCR1 deacetylation and increased its activity through SIRT3 (p <  0.05). Deacetylation of PYCR1 reversed the antitumor effect of CRIF1 knockdown (p <  0.05). Finally, knockdown of CRIF1 inhibited the tumor growth of NSCLC in vivo (p <  0.05).This research found that CRIF1 promoted the progression of non...
Source: Journal of Molecular Histology - Category: Laboratory Medicine Source Type: research